Skip to main content
L&C BIO Co., Ltd logo

L&C BIO Co., Ltd — Investor Relations & Filings

Ticker · 290650 ISIN · KR7290650001 KO Manufacturing
Open in API
Filings indexed 378 across all filing types
Latest filing 2022-10-04 Regulatory Filings
Country KR South Korea
Listing KO 290650

About L&C BIO Co., Ltd

http://www.lncbio.co.kr/?locale=en_US

L&C BIO Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company develops, manufactures, and commercializes human tissue-based medical devices and allograft treatment materials. Its core operations include the processing, storage, and distribution of human tissues, with a focus on skin, musculoskeletal, and soft tissues, utilizing patented processing technologies. The company's product portfolio also extends to other medical devices and cosmetics. L&C BIO supports its activities through dedicated research and development centers and manufacturing facilities, including a human tissue plant and a pharmaceutical plant, to advance its pipeline and serve global markets.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시)(수화형태 무세포화 피부대체재 및 그 제조방법에 대한 특허권취득)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) from L&C Bio regarding the acquisition of a patent for a 'hydrated acellular skin substitute and its manufacturing method'. It details the patent title, content, holder, and utilization plan. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2022-10-04 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price of convertible bonds (CB) due to a decline in the market price of the company's stock. This type of filing is a standard corporate disclosure related to capital structure and financing instruments. Since it details a change in the terms of existing financial instruments (convertible bonds) rather than a new share issue or a general regulatory notice, it falls under the 'Capital/Financing Update' category.
2022-09-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and contractual obligations (such as collateral agreements) of a major shareholder (Lee Whan-chul) in L&C Bio. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-09-29 Korean
기타경영사항(자율공시)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) by L&C Bio regarding the acquisition of a patent for a medical composition derived from adipose tissue. It details the patent title, content, and utilization plan. Since this is a regulatory disclosure of a specific corporate event (patent acquisition) that does not fit into financial reporting, M&A, or other specific categories, it is classified as a general regulatory filing.
2022-08-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard Korean regulatory filing for reporting significant changes in share ownership (often referred to as the 5% rule filing). It details the reporter (Lee Whan-chul), the issuer (L&C Bio), and the specific changes in shareholding and contractual obligations (collateral agreements and exchangeable bonds). This falls under the 'Major Shareholding Notification' category.
2022-08-26 Korean
교환사채권발행결정(종속회사의주요경영사항)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a South Korean company (L&C Bio) detailing the issuance of exchangeable bonds (EB) by its subsidiary. It includes specific financial terms such as interest rates, maturity dates, exchange ratios, and the purpose of the funds. This type of disclosure regarding capital structure changes and financing activities falls under the 'Capital/Financing Update' category.
2022-08-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.